Last reviewed · How we verify
Berberine placebo tablets
This is a placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials.
At a glance
| Generic name | Berberine placebo tablets |
|---|---|
| Sponsor | Second Xiangya Hospital of Central South University |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Berberine placebo tablets are inert tablets designed to match the appearance and administration schedule of active berberine formulations in randomized controlled trials. They serve as the control arm to assess the efficacy and safety of berberine by comparison against a non-therapeutic baseline. No pharmacological mechanism is present in the placebo itself.
Approved indications
Common side effects
Key clinical trials
- Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms (NA)
- Berberine Improving Cognitive Impairments in Schizophrenia (NA)
- A Clinical Study to Evaluate the Effects of Akkermansia Muciniphila and Berberine on Prediabetes Among Obese Subjects. (NA)
- Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia (PHASE4)
- Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine (PHASE2, PHASE3)
- 6-year Follow-up Data After the Berberine Intervention Trial
- Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis (PHASE4)
- Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: